NEWS RELEASES
Search all of our news releases here.
Addimmune, a Clinical Stage HIV-Focused Gene Therapy Company, to Go Public Through Business Combination with 10X Capital Venture Acquisition Corp. III
Addimmune’s investigational cell therapy, AGT103-T, makes gene modifications to the patients’ immune cells (T cells) that harden those cells against HIV infection and depletion, thus allowing those cells to target and kill HIV instead of being “killed” by the virus. Thirty-eight million people are living…
Read More
American Gene Technologies® Launches New Spinoff Company “Addimmune™” to Focus Exclusively on Development of HIV Cure
Addimmune will build upon the success of American Gene Technologies Phase 1 HIV clinical trial, accelerating the clinical development with dedicated investment and singular focus on HIV. (Rockville, Maryland – June 9, 2023) American Gene Technologies (AGT™), a clinical-stage biotechnology company based in Rockville,…
Read More
American Gene Technologies® Video Series “The Cure Chronicles” Wins BioBuzz Media Award
The Groundbreaking Series Features Engaging Conversations with People Living with HIV, Advocates and Medical Experts Striving Toward the Shared Goal of Ending HIV “The Cure Chronicles,” an innovative video series launched by Maryland biotechnology company, American Gene Technologies, is the winner of the third…
Read More
American Gene Technologies® CEO Jeff Galvin Wins Life Sciences Voice Top Industry Leaders Award
American Gene™ founder recognized as one of the field’s most dynamic leaders. Jeff Galvin, CEO and founder of American Gene Technologies®, a clinical-stage biotechnology company based in Rockville, Maryland, has been awarded the Life Sciences Voice Top Industry Leaders Award. The award recognizes the most…
Read More
American Gene Technologies® Phase I HIV Gene Therapy Clinical Trial Data Published in Frontiers Journal Shows Success in Safety & Durability
American Gene™ Plans for Phase 2 Trial of AGT103-T American Gene Technologies®, a clinical-stage biotechnology company based in Rockville, Maryland, has recorded data that meets the primary and secondary endpoints of its AGT103-T Phase 1 trial. The Phase 1 trial demonstrated that AGT103-T – an…
Read More
American Gene Technologies® Chief Medical Officer Honored by UCSF Endowment for HIV Dermatology and LGBTQ Health Research
Dr. Marcus Conant Named in UCSF’s Commitment to Pave Way for Next Generation of HIV Researchers American Gene Technologies, a clinical-stage biotechnology company based in Rockville, Maryland, congratulates Dr. Marcus Conant and the University of California San Francisco (UCSF) Medical Center’s Department of Dermatology for…
Read More
American Gene Technologies® Welcomes Barry H. Wells, M.D., as Head of Business Development
Dr. Wells’ promotion comes as the company’s HIV clinical trial progresses American Gene Technologies, a clinical-stage biotechnology company based in Rockville, Maryland, has promoted Barry H. Wells, M.D. as head of business development. Dr. Wells joined the company’s investor relations team in 2019. “I…
Read More
American Gene Technologies® HIV Cure Clinical Trial Enters Critical Phase: Withdrawing Participants from Antiretrovirals
Beginning the analytic treatment interruption is a pivotal step to potentially demonstrating a gene therapy cure for HIV. American Gene Technologies, a clinical-stage biotechnology company, has reached a turning point in its HIV cure clinical trial: it began withdrawing participants from their antiretroviral drugs earlier…
Read More
American Gene Technologies® Appoints Dr. Jeff Boyle as Chief Science Officer
Dr. Boyle’s biotech and intellectual property expertise strengthen the team as the company proceeds to next phase of its HIV cure clinical trial American Gene Technologies, a clinical-stage biotechnology company, has appointed Jeff Boyle, PhD as chief science officer. Dr. Boyle comes to the post…
Read More
American Gene Technologies® Attracts Investment from Ride Wave Ventures
AGT™ welcomes additional support of its HIV Cure clinical trial and broad gene therapy development platform American Gene Technologies, a clinical-stage biotechnology company working to cure HIV, announced today that angel investor Ride Wave Ventures has made its first investment in the company. Ride…
Read MoreSubscribe to News Releases and News Updates
Subscribe to our news release and published article updates to be notified when we release new content!
Follow AGT on Social Media
AGT on Facebook
Nick Tressler, MBA | People on The Move - Washington Business Journal
bit.ly
Nick Tressler, MBA Hired at Addimmune™ / American Gene Technologies®
